Search the Newsreel

Is FuelCell Energy (FCEL) Fairly Valued As Carbon Capture Draws Fresh Attention?

FuelCell Energy (FCEL) is gaining renewed interest due to its carbon capture platform, which reduces emissions and produces additional electricity. Despite recent stock volatility, the company's valuation narrative suggests it is 13% undervalued at $22 per share, driven by anticipated revenue growth from partnerships …

(OMCL) Price Dynamics and Execution-Aware Positioning

Omnicell Inc. (NASDAQ: OMCL) is exhibiting choppy conditions due to divergent sentiment across all time horizons, with support currently being tested. The AI models have generated three distinct trading strategies: a Position Trading Strategy, a Momentum Breakout Strategy, and a Risk Hedging Strategy, each …

AbCellera Biologics (ABCL) Stock Sees Fair Value Lift After Clinical Data And Jazz Deal

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. The latest analyst update on AbCellera Biologics reflects a higher Fair Value estimate of …

Antony Waste posts Q1 revenue growth but margins and profit slump

AbCellera Biologics (ABCL) On ABCL635 Trial Results And A Richer Valuation Story

FuelCell Energy Inc (FCEL) Shares Fall 3.2% -- GF Value Says Still Overvalued

FuelCell Energy Inc (FCEL) shares dropped 3.2% to $19.20, continuing a recent decline despite a significant 371.8% increase over the past year. GuruFocus' GF Value estimates the stock is significantly overvalued at $7.09, indicating a lack of safety margin for investors. While insiders have …

3 AI And Data Analytics Stocks Worth Watching Right Now

This article highlights three AI and data analytics stocks—Cellebrite DI (CLBT), Tenable Holdings (TENB), and Similarweb (SMWB)—that are worth watching due to their strategic positions in emerging technology areas. It details their operations, market caps, and why they stand out, such as Cellebrite's role …

Why Celldex Therapeutics (CLDX) Is Up 10.7% After Wider Losses And Barzolvolimab Phase 3 Progress

Celldex Therapeutics (CLDX) reported wider Q2 and first-half losses totaling US$73.5 million and US$152.19 million, respectively, yet its stock rose by 10.7%. This increase is attributed to positive Phase 1 data for bispecific antibody CDX-622 and continued Phase 3 progress for barzolvolimab, despite minimal …

Regencell Bioscience (RGC) Short Interest & Short Float | Updated Aug 2026 $RGC

Regencell Bioscience (RGC) had a short interest of 903,042 shares as of July 31, 2026, which is a 2.91% decrease from the previous report. This represents 0.18% of its public float, with a short interest ratio of 4.1 days to cover. The article provides …

FuelCell Energy Inc. stock falls Tuesday, underperforms market

FuelCell Energy Inc. (FCEL) stock dropped 3.18% to $19.20 on Tuesday, underperforming the broader market. This marks the second consecutive day of losses for the company, as the NASDAQ Composite Index and Dow Jones Industrial Average also saw declines.

AbCellera stock falls on $200M public offering launch

AbCellera Biologics Inc. (NASDAQ:ABCL) shares dropped 3.7% after the company announced a $200 million underwritten public offering of common stock and pre-funded warrants. The biotechnology company intends to use the net proceeds to fund research, development, and clinical advancement of its internal pipeline, including …

Cellebrite Di Ltd. (CLBT) executive Thomas E. Hogan plans large share sale

Cellebrite Di Ltd. executive Thomas E. Hogan has filed a Form 144 notice indicating his intent to sell 339,484 ordinary shares through Morgan Stanley Smith Barney LLC on or around August 12, 2026. These shares were acquired on August 11, 2026, as Performance Shares …

Truist Financial Issues Positive Forecast for AbCellera Biologics (NASDAQ:ABCL) Stock Price

Antony Waste Handling Cell Q1 Results: Earnings call audio uploaded

AbCellera Biologics (NASDAQ:ABCL) Stock Price Up 8.7% - Here's What Happened

Transcript : Antony Waste Handling Cell Limited, Q1 2027 Earnings Call, Aug 11, 2026

Can FCEL Boost Returns From Existing Fossil-Fuel Plants?

FuelCell Energy's FCEL carbon capture platform is designed to address the growing economic challenges facing aging coal and natural gas power plants. Tightening emissions requirements are raising compliance expenses, while permanently retiring these facilities can be costly, disruptive and politically difficult. Many of these …

HC Wainwright Issues Optimistic Forecast for CLDX Earnings

AWHCL: Q1 revenue up 6% year-on-year, but margins compressed due to one-offs; growth to accelerate in H2

Cellectis S.A. (NASDAQ:CLLS) Given Consensus Rating of "Moderate Buy" by Analysts

Cellectis S.A. (NASDAQ:CLLS) has received a consensus rating of "Moderate Buy" from analysts, with an average 12-month price target of $7.00. Despite exceeding EPS estimates in its latest quarter with an adjusted loss of $0.22 per share, the company's revenue of $6.9 million missed …

Quantinno Capital Management LP Buys 42,158 Shares of Celldex Therapeutics, Inc. $CLDX

Quantinno Capital Management LP significantly increased its stake in Celldex Therapeutics (NASDAQ:CLDX) by 178.7% in the first quarter, purchasing an additional 42,158 shares to own a total of 65,744 shares valued at $2.09 million. This move comes as institutional investors continue to adjust their …

Antony Waste Handling Cell PAT drops 97% in Q1FY27 on cost pressures

Fine Organic, Cello World, Ellenbarrie Q1 Review — Check Motilal Oswal's New Target Prices, Ratings, Upside

Empery Asset Management, LP Initiates Position in Cellectar Biosciences Inc (CLRB)

Empery Asset Management, LP has initiated a new position in Cellectar Biosciences Inc (CLRB) by purchasing 864,090 shares, representing 2.81% of its portfolio. This investment reflects Empery's focus on small-cap healthcare companies, despite CLRB's significant stock decline and poor financial health. Cellectar Biosciences is …

Results: Cello World Limited Beat Earnings Expectations And Analysts Now Have New Forecasts

What's Going On With Briacell Therapeutics Corp Stock Monday?

Millennium reports 3.8% Omnicell (OMCL) stake in amended 13G filing

Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have collectively reported a beneficial ownership of 1,734,375 shares of Omnicell, Inc. (OMCL) common stock, which represents 3.8% of the outstanding class. This disclosure was made in an amended 13G filing, indicating shared …

AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026

AbCellera (Nasdaq: ABCL) is set to release top-line data from its Phase 2 trial of ABCL635 for moderate-to-severe vasomotor symptoms (VMS) due to menopause on Monday, August 10, 2026. The company will also host an investor conference call and webcast to discuss the results. …

AbCellera (ABCL) Rockets 44% as Hot Flash Treatment Brightens Growth Outlook

AbCellera Biologics (ABCL) surged 44% to a three-year high following positive clinical trial results for its hot flash treatment, ABCL635. The drug significantly reduced hot flashes in postmenopausal women, outperforming a placebo, and analysts are bullish on its potential in a large addressable market. …

Cellectar Biosciences Sets Major Conference Schedule: Pediatric Cancer Data Featured

Cellectar Biosciences (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company, announced its participation in five major medical and industry conferences throughout September 2025. COO Jarrod Longcor will present on the company's Phospholipid Drug Conjugate™ (PDC) platform, including its lead asset iopofosine I 131, with notable …

AbCellera stock soars on ‘off the chart’ trial results from hot flash treatment for menopausal women

AbCellera Biologics Inc. saw its stock soar after announcing "off the chart" human trial results for its hot flash treatment, ABCL635, which proved more effective and had fewer side effects than existing therapies. The drug, aimed at menopausal women and those undergoing hormone-suppressing cancer …

AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile

AbCellera has announced positive top-line results from its Phase 2 clinical trial for ABCL635, an investigational antibody for treating moderate-to-severe vasomotor symptoms (hot flashes) in menopausal women. The study demonstrated statistically significant reductions in both the frequency and severity of symptoms, as well as …

Is Millicom International Cellular (TIGO) Fully Valued After Earnings And Its New Interim Dividend?

AbCellera Biologics Sees Unusually High Options Volume (NASDAQ:ABCL)

AbCellera Biologics (NASDAQ:ABCL) experienced unusually high options trading volume, with investors purchasing 16,666 call options, a 151% increase over the average. The company's shares surged by $2.37 to $9.30 on heavy trading volume, despite missing analyst expectations for both earnings and revenue in its …

Antony Waste Handling Cell Limited Reports Earnings Results for the First Quarter Ended June 30, 2026

Abcellera Biologics stock hits 52-week high at 8.79 USD

Abcellera Biologics Inc. (ABCL) reached a 52-week high of $8.79, reflecting a 63% total return over the past year and 119% over six months. Despite this, an InvestingPro analysis suggests the stock may be overvalued. The company also announced positive Phase 2 clinical trial …